Diabetic Retinopathy Market Report 2032: Epidemiology, Market Size, Share, Therapies, Clinical Trials, Companies & Growth Analysis Report - Segmented By Therapies, Countries, by DelveInsight | Genentech, Regeneron, Roche, Opthea Limited, Regenxbio, Kodiak

(Albany, USA) DelveInsight's "Diabetic retinopathy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Diabetic retinopathy, historical and forecasted epidemiology as well as the Diabetic retinopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Diabetic retinopathy market report presents information on the current treatment methods, newly developed drugs, the market share of specific therapies, and the anticipated size of the Diabetic retinopathy market from 2019 to 2032. The report is divided into segments covering seven major markets. Additionally, it includes details about the existing treatment practices and algorithms for Diabetic retinopathy, along with factors driving the market, obstacles faced, and areas of medical need that are yet to be addressed. By analyzing these factors, the report identifies promising opportunities and evaluates the potential growth of the Diabetic retinopathy market.

To know more about the Diabetic retinopathy market analysis, click here @ https://www.delveinsight.com/report-store/diabetic-retinopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some facts of the Diabetic Retinopathy Market Report
• The Diabetic retinopathy market size in the seven major markets was found to be USD 126,851 million in 2021.
• Leading Diabetic Retinopathy Market Companies include Genentech, Inc., Regeneron Pharmaceuticals, Roche, Opthea Limited, Regenxbio, Kodiak Sciences Inc, Ocuphire Pharma, Eisai Co Ltd, Apexian Pharmaceuticals, Oculis, Bayer, Novartis Pharmaceuticals, Allegro Ophthalmics, LLC, Adverum Biotechnologies, Inc., Graybug Vision, Kubota Vision Inc., KalVista Pharmaceuticals Ltd., and others.
• Promising Diabetic Retinopathy Pipeline Therapies include PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection, Latanoprost, Lucentis, Octreotide Acetate in Microspheres 20 mg, KSI-301, and others.
• The total Diabetic Retinopathy prevalent cases in the 7MM were 12,585,769 in 2021.

Diabetic Retinopathy Overview
Diabetic retinopathy is a progressive eye disease that affects individuals with diabetes. It occurs due to damage to the blood vessels in the retina, the light-sensitive tissue at the back of the eye. Over time, high blood sugar levels can cause these blood vessels to become weak and leak or become blocked, leading to vision problems.
There are two main stages of diabetic retinopathy: non-proliferative and proliferative. In the non-proliferative stage, small blood vessels in the retina may leak, causing swelling or the formation of deposits called exudates. In the proliferative stage, new, abnormal blood vessels may develop on the surface of the retina, which are fragile and prone to bleeding. This can result in severe vision loss if left untreated.
People with diabetes should undergo regular eye examinations to detect and manage diabetic retinopathy. Treatment options include laser therapy to seal leaking blood vessels or inhibit the growth of abnormal vessels, injections of anti-vascular endothelial growth factor (VEGF) medications to reduce swelling and prevent new vessel formation, and, in severe cases, surgical intervention.
Proper management of diabetes, including blood sugar control, blood pressure control, and regular eye screenings, is crucial in preventing and managing diabetic retinopathy. Early detection and timely treatment can help preserve vision and prevent complications.

Request for Diabetic retinopathy sample report @ https://www.delveinsight.com/sample-request/diabetic-retinopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Diabetic Retinopathy Epidemiology Segmentation in the 7MM
• Total Diabetic Retinopathy Prevalent cases
• Diabetic Retinopathy Gender-specific
• Diabetic Retinopathy Severity-specific cases
• Diabetic Retinopathy Age-specific cases

Recent Developmental Activities in the Diabetic Retinopathy Treatment Landscape
• In May 2022, EyePoint Pharmaceuticals announced the EYP-1901 license to Betta Pharmaceuticals, to develop and commercialize EYP-1901 in China, Hong Kong, Macau, and Taiwan. EyePoint retains all rights for EYP-1901 in the rest of the world and expands its exclusive rights to local delivery of vorolanib for the treatment of all ophthalmic diseases, including diabetic macular edema (DME). Phase 2 clinical trial for EYP-1901 in non-proliferative diabetic retinopathy (NPDR) is expected to initiate in 2H 2022.
• In April 2022, Ocuphire Pharma presented masked safety data from the ongoing ZETA-1 Phase 2b trial of oral APX3330 for the treatment of diabetic retinopathy. The results show a favorable ophthalmic and systemic safety and tolerability profile, consistent with 11 prior safety trials of APX3330 in non-ophthalmic indications. The company expects to report top-line results from the ZETA-1 trial in the second half of 2022.
• In January 2022, Ocuphire Pharma entered into an agreement with Apexian Pharmaceuticals, Inc., granting Ocuphire an exclusive worldwide sublicense to Apexian's Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all ophthalmic and diabetic indications.
• The Therapeutic candidate KSI-301, currently in clinical development being produced by Kodiak Sciences is a novel anti-VEGF biologic designed to have an extended ocular half-life. KSI-301 is being developed in Phase III stage of Diabetic Retinopathy Pipeline development towards a once every four to six-month treatment regimen - a possible game changer that may provide the opportunity for real prevention.
• Brolucizumab (RTH258) is a humanized single-chain antibody fragment (scFv) and the most clinically advanced, humanized single-chain antibody fragment developed by Novartis. Currently, it is in the Phase III stage of development to treat Diabetic Retinopathy.

To know more about Emerging Diabetic Retinopathy Drugs & Companies, visit @ @ https://www.delveinsight.com/sample-request/diabetic-retinopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Diabetic Retinopathy Emerging Drugs Profile
• OPT-302: Opthea Limited
OPT-302 is a first-in-class VEGF-C/D inhibitor. It is a soluble fusion protein comprising immunoglobulin-like domains 1 to 3 of the extracellular domain of vascular endothelial growth factor receptor 3 (VEGFR-3) fused to the Fc fragment of human immunoglobulin G1 (IgG1) (Opthea, 2019). OPT-302 is a soluble form of VEGFR-3 which binds ("traps") human VEGF-C and VEGF-D with high affinity, neutralizing their activity by preventing them from binding to both VEGFR-2 and VEGFR-3 (Opthea, 2019).
• RGX 314: Regenxbio
It is being investigated as a potential one-time treatment for wet AMD, diabetic retinopathy, and other chronic retinal conditions. RGX-314 consists of the NAV AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF). RGX-314 is believed to inhibit the VEGF pathway by which new, leaky blood vessels grow and contribute to the fluid accumulation in the retina.
• Runcaciguat (BAY 1101042): Bayer
The sGC enzyme, via the formation of cyclic guanosine monophoshphate, is a key regulator of body and tissue homeostasis. sGC activators with their unique mode of action are activating the oxidized and heme-free and therefore NO-unresponsive form of sGC, which is formed under oxidative stress. Runcaciguat is currently investigated in clinical phase 2 studies for the treatment of patients with chronic kidney disease and nonproliferative diabetic retinopathy (Hahn et al., 2021).

Diabetic Retinopathy Market Dynamics
The dynamics of the Diabetic Retinopathy market are expected to undergo changes in the future due to advancements in diagnostic methods and increased healthcare expenditure worldwide. The forecast period from 2022 to 2032 is predicted to witness the introduction of numerous emerging therapies. The developmental pipeline for Diabetic Retinopathy is robust, with several products in various stages of development. Key players such as Genentech, Inc., Regeneron Pharmaceuticals, Roche, Opthea Limited, Regenxbio, Kodiak Sciences Inc, Ocuphire Pharma, Eisai Co Ltd, Apexian Pharmaceuticals, Oculis, Bayer, Novartis Pharmaceuticals, Allegro Ophthalmics, LLC, Adverum Biotechnologies, Inc., Graybug Vision, Kubota Vision Inc., KalVista Pharmaceuticals Ltd., and others are actively involved in developing promising products for this condition.

Learn more about the Diabetic Retinopathy Pipeline Therapies in clinical trials @ https://www.delveinsight.com/sample-request/diabetic-retinopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Diabetic Retinopathy Market Report
• Coverage- 7MM
• Diabetic Retinopathy Companies- Regeneron Pharmaceuticals (NYSE: REGN), Roche NYSE: ROG), Opthea Limited (NYSE: OPT), Regenxbio (NYSE: RGNX), Kodiak Sciences Inc (NYS: KOD), Ocuphire Pharma (NYSE: OCUP), Eisai Co Ltd (NYSE: ESALY), Apexian Pharmaceuticals, Oculis, Bayer, Novartis Pharmaceuticals (NYSE: NVS), Allegro Ophthalmics LLC, Adverum Biotechnologies Inc, (NYSE: ADVM), Graybug Vision (NYSE: GRAY), Kubota Vision Inc (NYSE: KUBTY)., KalVista Pharmaceuticals Ltd (NYSE: KALV), and others.
• Diabetic Retinopathy Pipeline Therapies- PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection, Latanoprost, Lucentis, Octreotide Acetate in Microspheres 20 mg, KSI-301, and others.
• Diabetic Retinopathy Market Dynamics: Diabetic Retinopathy Market Drivers and Barriers
• Diabetic Retinopathy Market Access and Reimbursement, Unmet Needs, Future Perspectives

Discover more about Diabetic Retinopathy Drugs in development @ https://www.delveinsight.com/sample-request/diabetic-retinopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Key Insights
2. Diabetic Retinopathy Report Introduction
3. Diabetic Retinopathy Market Overview at a Glance
4. Executive Summary of Diabetic Retinopathy
5. Disease Background and Overview
6. Diabetic Retinopathy Management and Treatment
7. Diabetic Retinopathy Epidemiology and Patient Population
8. Diabetic Retinopathy Patient Journey 1
9. Diabetic Retinopathy Patient Journey 2
10. Diabetic Retinopathy Market Outlook
11. Diabetic Retinopathy Marketed Drugs
12. Diabetic Retinopathy Emerging Drugs
13. Other Therapy
14. Diabetic Retinopathy Market Analysis : 7MM
15. Diabetic Retinopathy Market Drivers
16. Diabetic Retinopathy Market Barriers
17. Diabetic Retinopathy KOL Views
18. Diabetic Retinopathy SWOT Analysis
19. Diabetic Retinopathy Unmet Needs
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Trending Reports:
• Anaphylaxis Market: https://www.delveinsight.com/report-store/anaphylaxis-market
• Aortic Stenosis Market: https://www.delveinsight.com/report-store/aortic-stenosis-market
• Cluster Headaches Market: https://www.delveinsight.com/report-store/cluster-headache-market
• Familial Primary Pulmonary Hypertension Market: https://www.delveinsight.com/report-store/familial-primary-pulmonary-hypertension-market
• Hpv-induced Cancers Market: https://www.delveinsight.com/report-store/hpv-induced-cancers-market
• Meningioma Market: https://www.delveinsight.com/report-store/meningioma-market
• Optic Neuritis Market: https://www.delveinsight.com/report-store/optic-neuritis-market
• Partial Seizure Market: https://www.delveinsight.com/report-store/partial-seizure-market
• Progressive Multifocal Leukoencephalopathy Market: https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-market
• Rhino Conjunctivitis Market: https://www.delveinsight.com/report-store/rhino-conjunctivitis-market
• Thymic Carcinoma Market: https://www.delveinsight.com/report-store/thymic-carcinoma-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Chronic Lymphocytic Leukemia Market: https://www.delveinsight.com/report-store/relapsed-chronic-lymphocytic-leukemia-cll-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Aesthetic Implants Market: https://www.delveinsight.com/report-store/aesthetic-implants-market
• Multiple Myeloma Market: https://www.delveinsight.com/report-store/multiple-myeloma-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Lewy Body Dementia Market: https://www.delveinsight.com/report-store/lewy-body-dementia-market
• Alopecia Market: https://www.delveinsight.com/report-store/alopecia-market
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Pruritus Market: https://www.delveinsight.com/report-store/pruritus-market
• Eczema Market: https://www.delveinsight.com/report-store/eczema-market
• Concussions Market Size: https://www.delveinsight.com/report-store/concussions-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Actinic Keratosis Market: https://www.delveinsight.com/report-store/actinic-keratosis-market
• Alzheimer Disease Market: https://www.delveinsight.com/report-store/alzheimers-disease-ad-market
• Chemotherapy Induced Thrombocytopenia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-thrombocytopenia-market-size
• Foot And Ankle Devices Market: https://www.delveinsight.com/report-store/foot-and-ankle-devices-market
• Parkinson's Disease Market: https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment
• Ventilator Market: https://www.delveinsight.com/report-store/ventilators-market

Contact Us:

Ankit Nigam
info@delveinsight.com
+1(919)321-6187
https://www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.